Copper-to-Zinc Ratio Correlates with an Inflammatory Marker in Patients with Sickle Cell Disease (Version 2, Revised)
|Reviewer 1 Jungshan Chang Taipei Medical University||Reviewer 2 Muhammad Jawad Nasim Saarland University, Saarbruecken, Germany|
Approved with revisions
|Approved with revisions|
Emokpae, M.A.; Fatimehin, E.B. Copper-to-Zinc Ratio Correlates with an Inflammatory Marker in Patients with Sickle Cell Disease. Sci 2019, 1, 55.
Emokpae MA, Fatimehin EB. Copper-to-Zinc Ratio Correlates with an Inflammatory Marker in Patients with Sickle Cell Disease. Sci. 2019; 1(2):55.Chicago/Turabian Style
Emokpae, Mathias A.; Fatimehin, Emmanuel B. 2019. "Copper-to-Zinc Ratio Correlates with an Inflammatory Marker in Patients with Sickle Cell Disease." Sci 1, no. 2: 55.
Article Access Statistics
Taipei Medical University
This finding was really correlated or similar to the discovery by the Antwi-Boasiako research group published in the Medicina 2019, 55(5), 180 with the title of Serum Iron Levels and Copper-to-Zinc Ratio in Sickle Cell Disease. This study came with better research designed and more insightful results and conclusion. It also demonstrated that the copper-to-zinc ratio was significantly higher in the SCD patients, suggesting elevated copper-to-zinc ratio may be a biomarker of sickle cell oxidative stress and associated complications. The ratio may also be informative for the management of sickle cell oxidative burden. The authors suggested increased correlates with an Inflammatory Marker in Patients with Sickle Cell. This published article does impair the value of your studies and manuscript.
Response to Reviewer 1Sent on 15 Jul 2020 by Mathias, Abiodun Emokpae, Emmanuel, Babatunde Fatimehin
Saarland University, Saarbruecken, Germany
Authors report correlation of serum levels of copper, zinc, copper-to-zinc ratio with an inflammatory marker (c-reactive protein) in the patients with sickle cell anemia in the population of Nigeria. It is a very interesting study which confirms the correlation of abovementioned parameters towards the inflammation in the patients of sickle cell disease. A similar study has been reported by the Antwi-Boasiako research group published in the Medicina 2019, 55(5), 180 which also includes the serum levels of iron as an additional contributing factor. Moreover, the study reported by the Antwi-Boasiako et al was carried out in Ghana so it will be interesting to correlate both studies to provide a broader overview of the scope of the study. Over all it a very nice manuscript but can be improved.